Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 12/20 | 0.67 |
| ▸ | ITGA4 | P13612 | 11/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | DDX3X | O00571 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGAV | P06756 | 1/20 | 0.57 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612679 | 1.00 | ITGB1 (0.67) | ITGB1ITGA4POLBFFAR1MAPT | |
| SCHEMBL14558951 | 0.89 | FFAR1 (0.60) | ITGB1ITGA4POLBFFAR1MEN1 | |
| SCHEMBL8231040 | 0.88 | ITGB1 (0.61) | ITGB1ITGA4POLBMAPTRAB9A | |
| SCHEMBL20808405 | 0.87 | ITGB1 (0.59) | ITGB1ITGA4POLBMAPTRAB9A | |
| SCHEMBL5154921 | 0.86 | ALDH1A1 (0.64) | ITGB1ITGA4POLBFFAR1MAPT | |
| SCHEMBL18472821 | 0.86 | ITGB1 (0.58) | ITGB1ITGA4POLBMAPTRAB9A | |
| SCHEMBL7381546 | 0.86 | ITGB1 (0.71) | ITGB1ITGA4POLBMAPTRAB9A | |
| SCHEMBL5155328 | 0.85 | ITGB1 (0.57) | ITGB1ITGA4POLBMEN1KMT2A | |
| SCHEMBL14561170 | 0.85 | RAB9A (0.67) | ITGB1ITGA4POLBMAPTRAB9A | |
| SCHEMBL7104543 | 0.85 | RAB9A (0.62) | ITGB1ITGA4MAPTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594340-B2 | Treating inflammation using LLP2A-bisphosphonate conjugates and mesenchymal stem cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260000775-A1 | a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| CN-119930738-A | The method comprises the following steps of68Ga-marked molecular probe targeting VLA-4, preparation method and application thereof | 江苏省原子医学研究所 | 2025-05-06 | — | — | CN | disclosed |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-03 | — | — | US | disclosed |
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-114846030-A | Novel conjugation chemistry that catalyzes antibody 38C2 | 佛罗里达大学研究基金会公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114159580-A | Treatment of inflammation with LLP 2A-bisphosphonate conjugates and mesenchymal stem cells | 加利福尼亚大学董事会 | 2022-03-11 | — | — | CN | disclosed |
| US-20210401993-A1 | TREATING INFLAMMATION USING LLP2A-BISPHOSPHONATE CONJUGATES AND MESENCHYMAL STEM CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210395302-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | disclosed |
| US-6020347-A | 4-substituted-4-piperidine carboxamide derivatives | MERCK & CO., INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-2000000477-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999054321-A1 | SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999033789-A1 | SUBSTITUTED β-ALANINES | AVENTIS PHARMA LIMITED (GB) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999025685-A1 | 4-SUBSTITUTED-4-PIPERIDINE CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0917462-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1999-05-26 | — | — | EP | disclosed |
| WO-1999023063-A1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LIMITED (GB) | 1999-05-14 | — | — | WO | disclosed |
| EP-0842196-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1998004247-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997003094-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395302-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | ITGB4, ITGA4, ITGB1 | ITGB1 3/4885ITGA4 2/4885POLB 4364/4885 |
| US-20260000775-A1 | a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ITGB1, ITGB4, ITGA4 | ITGB1 1/4885ITGA4 3/4885POLB 2005/4885 |
| US-20210401993-A1 | TREATING INFLAMMATION USING LLP2A-BISPHOSPHONATE CONJUGATES AND MESENCHYMAL STEM CELLS | LCP2, BST2, LCP1 | ITGB1 2841/4885ITGA4 2494/4885POLB 4022/4885 |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | ITGB4, ITGA4, ITGB1 | ITGB1 3/4885ITGA4 2/4885POLB 4364/4885 |
| US-12594340-B2 | Treating inflammation using LLP2A-bisphosphonate conjugates and mesenchymal stem cells | LCP2, CALCB, BST2 | ITGB1 1363/4885ITGA4 948/4885POLB 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.